A case report: Liraglutide as a novel treatment option in late dumping syndrome.
Medicine (Baltimore) · 2017
Last updated 2026-05-28A patient with late dumping syndrome—low blood sugar after meals following stomach surgery—was treated with liraglutide injections at doses of 0.6 mg and 1.2 mg per day. The treatment reduced insulin spikes and improved symptoms of low blood sugar, suggesting liraglutide may be a new option for this condition.
AI summary of the abstract below.
| Journal | Medicine (Baltimore), 2017 |
|---|---|
| Citations | 18 |
| Relative citation ratio | 0.97 |
| NIH percentile | 49 |
| Molecules | liraglutide |
Abstract
RATIONALE: Postprandial hyperinsulinemic hypoglycemia, known as late dumping syndrome, is a rare but often misdiagnosed complication after gastric surgery. The pathophysiological mechanisms are poorly understood and the treatment of this syndrome is challenging.
PATIENT CONCERNS: New-onset postsurgical late dumping syndrome after Toupet fundoplication.
DIAGNOSES: Sigstad Score, OGTT, CGM.
INTERVENTIONS: Daily subcutaneous injection of liraglutide (0.6 mg and 1.2 mg).
OUTCOMES: Reduction in fasting and postprandial peak insulin level with improvement in symptomatic hypoglycemic events.
LESSONS: Liraglutide may be a novel treatment option for postprandial hyperinsulinemic hypoglycemia after gastric surgery.
Verbatim abstract via PubMed 28328816 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.